Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC)

J Immunother. 2016 Jun;39(5):202-4. doi: 10.1097/CJI.0000000000000121.

Abstract

Immunomodulatory agents that target PD-1 and its ligand (PD-L1) are being increasingly used in the management of lung cancer. Potential immune-related adverse events include dermatological complications which mostly are of low grade severity. The use of immune checkpoint inhibitors may lead to the exacerbation of autoimmune conditions. We report a case of a documented psoriasis flare with anti-PD-1 treatment for lung cancer.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / immunology
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Aged
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use
  • B7-H1 Antigen / immunology
  • Calcitriol / analogs & derivatives
  • Calcitriol / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Cigarette Smoking
  • Disease Progression
  • ErbB Receptors / genetics*
  • Exons / genetics
  • Humans
  • Male
  • Mometasone Furoate / therapeutic use
  • Neoplasm Metastasis
  • Phototherapy
  • Psoriasis / etiology
  • Psoriasis / prevention & control*
  • Sequence Deletion / genetics

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • B7-H1 Antigen
  • Mometasone Furoate
  • calcipotriene
  • ErbB Receptors
  • Calcitriol